Baird Upgrades Qiagen to Outperform, Lowers Price Target to $43
Benzinga Newsdesk 6 months ago
NewsUpgradesPrice TargetAnalyst Ratings
Baird analyst Catherine Schulte upgrades Qiagen (NYSE:QGEN) from Neutral to Outperform and lowers the price target from $53 to $43.
Baird analyst Catherine Schulte upgrades Qiagen (NYSE:QGEN) from Neutral to Outperform and lowers the price target from $53 to $43.